[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355443-105":59,"doc-detail-355443-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","artificial-intelligence-powered-liquid-biopsy-in-cancer-a-paradigm-shift-in-cancer-detection-and-personalized-care","Artificial intelligence-powered liquid biopsy in cancer - a paradigm shift in cancer detection and personalized care","","Liquid biopsy has evolved as a transformative strategy revolutionizing oncology by detecting circulating biomarkers such as circulating tumor DNA, extracellular vesicles, tumor-educated platelets, circulating tumor cells, and circulating RNAs in body fluids. Clinical use remains limited by constrained sensitivity, specificity, and insufficient standardization. This review evaluates how artificial intelligence and machine learning can address these barriers and enable precision oncology. It focuses on breast, lung, colorectal cancers, and hepatocellular carcinoma, covering early detection, prognosis prediction, treatment response monitoring, recurrence forecasting, and patient stratification while discussing ethical issues and validation needs to support reproducible clinical adoption.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/artificial-intelligence-powered-liquid-biopsy-in-cancer-a-paradigm-shift-in-cancer-detection-and-personalized-care/355443/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/artificial-intelligence-powered-liquid-biopsy-in-cancer-a-paradigm-shift-in-cancer-detection-and-personalized-care/355443.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biomarkers are typically detected in liquid biopsy?","Question",{"text":112,"@type":113},"Liquid biopsy detects circulating biomarkers derived from tumors, including circulating tumor DNA, extracellular vesicles, tumor-educated platelets, circulating tumor cells, and circulating RNAs in body fluids.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitations restrict liquid biopsy in clinical practice?",{"text":117,"@type":113},"Clinical application is constrained by limited sensitivity and specificity, along with a lack of standardization.",{"name":119,"@type":110,"acceptedAnswer":120},"How can AI and machine learning improve liquid biopsy for cancer care?",{"text":121,"@type":113},"AI-powered liquid biopsy can enhance early detection, prognosis prediction, monitoring of treatment response, recurrence forecasting, and patient stratification, while addressing translational challenges and ethical considerations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355443,1790867936,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","AbdelHamid et al. Cancer Cell International (2026) 26:160 Cancer Cell International  \n[https://doi.org/10.1186/s12935-026-04263-w](https://doi.org/10.1186/s12935-026-04263-w)  \nREVIEW Open Access  \nArtificial intelligence-powered liquid biopsy in cancer: a paradigm shift in cancer detection and personalized care  \nSherihan G. AbdelHamid 1*, Esraa M. Halawa2, Eman M. Ibrahim3 and Mahmoud ElHefnawi4*  \nAbstract  \nLiquid biopsy has evolved as a transformative strategy revolutionizing the oncology field. It encompasses the detection of circulating biomarkers derived from tumors including circulating tumor DNA, extracellular vesicles, tumor educated platelets, circulating tumor cells, and circulating RNAs within body fluids. Nonetheless, its application in the clinical settings continues to be constrained by issues related to limited sensitivity, specificity, and lack of standardization. This review uniquely examines the convergence of artificial intelligence (AI) and machine learning (ML) algorithms with liquid biopsy to overcome these barriers and advance precision oncology. Focusing on four major malignancies; breast, lung, colorectal cancers, and hepatocellular carcinoma; we critically evaluate how AI-powered liquid biopsy improves early detection of cancer, prognosis prediction, and monitoring treatment response, while also forecasting recurrence and enabling patient stratification. We further highlight emerging algorithmic innovations, translational challenges, and ethical considerations, emphasizing the urgent need for harmonized validation frameworks to ensure reproducibility and clinical adoption. By leveraging AIdriven molecular insights, liquid biopsy can transition from a research concept to a routine clinical assay, enabling individualized therapeutic strategies, improving long-term survival, and ultimately transforming cancer care into amore predictive, personalized, and patient-centered paradigm.  \n*Correspondence:  \nSherihan G. AbdelHamid [dr.sherehan@pharma.asu.edu.eg](dr.sherehan@pharma.asu.edu.eg)[ ](dr.sherehan@pharma.asu.edu.eg)Mahmoud ElHefnawi [mahef@aucegypt.edu](mahef@aucegypt.edu)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nAbdelHamid et al. Cancer Cell International (2026) 26:160 Page 2 of 33  \n\n| Graphical |\n| --- |\n| Abstract\u003Cbr>|\n| Created in BioRender. Galal, S. (2026) [https://BioRender.com/1zu7u3r](https://BioRender.com/1zu7u3r)\u003Cbr>Keywords Artificial intelligence, Machine learning, Liquid biopsy, Breast cancer, Lung cancer, Colorectal cancer, Hepatocellular carcinoma |\n\nIntroduction  \nCancer poses substantial health burden worldwide, with forecasted increase in incident cases to 29 million by 2040 [1]. In order to address the global rise in cancer mortality rates, synchronized endeavors directed to early diagnosis, predicting prognosis and personalized treatment strategies are urgently needed to improve patients’outcomes and decrease the immense strain on healthcare systems worldwide. Current research in the field o","cbCaisiZTdV74cwm","https://ap.wps.com/l/cbCaisiZTdV74cwm","pdf",4306070,33,"English","# Abstract\n# Introduction\n## The foundation: understanding liquid biopsy and cancer prognosis\n## Liquid biopsy: a minimally invasive lens into cancer","[{\"question\":\"What biomarkers are typically detected in liquid biopsy?\",\"answer\":\"Liquid biopsy detects circulating biomarkers derived from tumors, including circulating tumor DNA, extracellular vesicles, tumor-educated platelets, circulating tumor cells, and circulating RNAs in body fluids.\"},{\"question\":\"What limitations restrict liquid biopsy in clinical practice?\",\"answer\":\"Clinical application is constrained by limited sensitivity and specificity, along with a lack of standardization.\"},{\"question\":\"How can AI and machine learning improve liquid biopsy for cancer care?\",\"answer\":\"AI-powered liquid biopsy can enhance early detection, prognosis prediction, monitoring of treatment response, recurrence forecasting, and patient stratification, while addressing translational challenges and ethical considerations.\"}]","Artificial intelligence-powered liquid biopsy in cancer - a paradigm shift in cancer detection and personalized care | PDF",1790118925,83,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0cf572ad84c2385a57abfb523425e5d.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/babbfbe6c969c0f3088bb176fd2cc2bd.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ede697a6a08a553b1bb9eecee3e6343b.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b55e70edb115152fd3a925bcc4f999a.webp",980,1306]